Vendor Intelligence Report: Paradigm Peptide

Published 13 Jun 2026. 23-page investigative report on who is behind Paradigm Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 18 Finnrick lab tests, Paradigm Peptide posts a 94% overall pass rate: 17 pass / 0 fail. That headline is strong, but the coverage is narrow. Finnrick data only reaches two GLP-1 products, and the buyer read is product-specific: Retatrutide is the cleaner tested choice, while Tirzepatide also passes but carries a repeated quantity-overfill pattern that makes label-based dosing less predictable.

The non-lab intelligence cuts the other way. Paradigm Peptide presents as a recent, small web operation: a privacy-protected 2025 domain, a Wix-built site, California warehouse language without a street address, and legal pages that do not name a corporate counterparty. A California Secretary of State exact-name search found no Paradigm Peptide entity, while the report’s location work points instead to a Central California operating footprint and a first-name-only operator lead.

The report also separates Paradigm Peptide from the older, non-hyphenated Paradigm Peptides operation tied to DOJ and ITC records. The evidence does not support treating them as the same vendor, but buyer confusion is real and documented. That makes official-domain verification, batch-specific COA verification, and caution around coupon or referral pages more important than the public A-style test badge alone.

For buyers, the practical read is not a blanket safe-or-unsafe verdict. Paradigm Peptide is a more defensible candidate for tested Retatrutide than for untested catalog items, and Tirzepatide needs batch-level quantity scrutiny despite a clean pass/fail identity record. Non-peptide injectables in the catalog sit outside Finnrick’s tested coverage.

Inside the full report:

  • Per-product Finnrick pass/fail interpretation and methodology-divergence charts for Retatrutide and Tirzepatide
  • Tirzepatide quantity-divergence analysis showing the overfill pattern without reducing it to a pass badge
  • Corporate-identity review using website terms, California registry search, RDAP, DNS, and archive records
  • Side-by-side separation of the subject hyphenated domain from the older Indiana Paradigm Peptides record
  • Catalog-boundary review covering untested peptides, non-peptide injectables, and missing on-site COA mechanisms
  • Affiliate, Substack, Reddit, coupon-page, and official-channel verification analysis

Risk assessment

  • Corporate opacity and short operating-history risk — medium: No legal entity name, street address, or owner is disclosed; California exact-name search found no entity and the domain was registered in 2025.
  • Brand-confusion and authenticity-verification risk — medium: Near-identical defunct Paradigm Peptides domain has DOJ/ITC history; subject disclaims affiliation but offers limited official-channel and COA verification signals.
  • Tirzepatide fill-accuracy risk — medium: Tirzepatide is 10/10 pass with 87.71% Finnrick rating, but Finnrick records show repeated overfill/quantity-divergence affecting label-based dosing.
  • Untested non-peptide injectable documentation risk — medium: Lemon Bottle, L-Carnitine, and Lipo-C are listed without visible on-site COAs and are outside Finnrick’s tested Retatrutide/Tirzepatide record.